Skip to content
SEC filings edition: Friday, November 13, 2026 · 767 companies with filings Publisher's serviceBoardeon, your AI board · Hire your board →
Monday, November 16, 2026Every business day from SEC EDGAR
SEC EDGAR · Nov 13, 2026 1bankruptcies 11delisting notices 12late filings 43leadership changes 6IPO filings 199private raises 90earnings releases
Company page · CIK 2131524 · BRVE

Braveheart Bio, Inc.

Filing with the SEC SEC-reporting company San Francisco, CA Nasdaq
An email when it files something new with the SEC. Your account

What this means

  • Stockholders’ deficitAt the end of 2025 stockholders’ equity was negative: −$65.9M (XBRL data filed with the SEC).

What to do next

Guides from the Companies Daily newsroom, picked for what the register shows.

Financials from XBRL

Calendar-year frame20252024
Total assets$89.4M—
Total liabilities$5.3M—
Stockholders’ equity−$65.9M$0
Cash and equivalents$89.2M$0

From XBRL data the company filed with the SEC (data.sec.gov frames, US GAAP, US dollars). A frame aligns the fiscal year with the calendar year closest to it; this company’s fiscal year ends December 31. Check the annual report for the exact figures and periods.

Name as filed
Braveheart Bio, Inc.
CIK
0002131524
Tickers
BRVE
Kind of filer
SEC-reporting company
Non-accelerated filer; Smaller reporting company; Emerging growth company
Status
Filing with the SEC
State of incorporation
Delaware
Business address
San Francisco, California
Industry (SIC)
2834 · Pharmaceutical preparations
Industry: D · Manufacturing →
Fiscal year ends
December 31
Last annual report
None in our data
Last quarterly report
10-Q for the quarter ended Sep 30, 2026
Bankruptcy reported
Not in our data
Last edition event
Nov 10, 2026

Filing history

Newest first: the filings we classify (8-K items, late filing notices, delistings, deregistration, IPO registrations, Schedule 13D, Form D, annual and quarterly reports), from Jan 1, 2023. All documents, including those we do not classify, are in the EDGAR filing index.

  • Quarterly report filed: 10-Q for the quarter ended Sep 30, 2026
    Form 10-Q · filed Nov 10, 2026 · filing · edition of Nov 10, 2026
  • Results announced
    Form 8-K · items 2.02, 9.01 · filed Nov 10, 2026 · filing · edition of Nov 10, 2026
  • Results announced
    Form 8-K · items 2.02, 9.01 · filed Sep 8, 2026 · filing
  • Quarterly report filed: 10-Q for the quarter ended Jun 30, 2026
    Form 10-Q · filed Sep 8, 2026 · filing
  • Stake of 5% or more with intent to influence: Schedule 13D: stake of 5% or more
    Form SCHEDULE 13D · filed Aug 18, 2026 · filing
  • Stake of 5% or more with intent to influence: Schedule 13D: stake of 5% or more
    Form SCHEDULE 13D · filed Aug 14, 2026 · filing
  • IPO prospectus (424B4): Final prospectus (424B4)
    Form 424B4 · filed Aug 6, 2026 · filing
  • IPO registration filed: Registration statement (S-1)
    Form S-1 · filed Jul 15, 2026 · filing